Rational Design of Doravirine: From Bench to Patients.
Sign Up to like & getrecommendations! Published in 2019 at "ACS infectious diseases"
DOI: 10.1021/acsinfecdis.9b00178
Abstract: Since the approval of nevirapine, the first HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) in 1996, NNRTIs have helped play a critical role in maintaining viral suppression in people living with HIV. The many positive attributes… read more here.
Keywords: doravirine; doravirine bench; rational design; bench patients ... See more keywords